Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Camrelizumab + Rivoceranib in hepatocellular carcinoma
NCT05320692Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Hengrui. Started Aug 2022; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05320692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320692.